Trial Profile

A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Saposin C (Primary)
Indications Brain cancer; Diffuse intrinsic pontine glioma; Glioma; Osteosarcoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms KOURAGE
Sponsors Bexion Pharmaceuticals

Most Recent Events

23 Feb 2023 According to Bexion Pharmaceuticals media release, results from this study have been published in the Volume 8, Issue 12, December, 2022, e12450 issue of Heliyon
23 Feb 2023 Results published in the Bexion Pharmaceuticals Media Release
11 Nov 2020 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com